Drug Combination Details
| General Information of the Combination (ID: C29558) | |||||
|---|---|---|---|---|---|
| Name | Tricin NP Info | + | Ganciclovir Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cytomegaloviral disease
[ICD-11: 1D82]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | pbp2a | Molecule Info | ||
| Biological
Regulation |
Reduction | Effective drug dose | ||||
| In-vitro Model | MRC-5 | CVCL_0440 | Healthy | Homo sapiens | ||
| Experimental
Result(s) |
Expression of the HCMV UL54 gene was significantly inhibited by combination of GCV with tricin when compared with GCV mono-treatment. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro. Antiviral Res. 2016 Jan;125:79-83. | |||
